You are invited to a lunch to learn about Focal Medical from Founder Jen Jen Yeh, M.D., CEO Tony Voiers, CTO William Daunch, Ph.D., and Spectrum Financial, one of the family offices invested in the company. 

Originating at the University of North Carolina and with initial funding from Khosla Ventures, Focal Medical has recently received FDA clearance of their IND to start a Phase 1B clinical trial in patients with pancreatic cancer. Dr. Yeh is a surgical oncologist and is an internationally recognized leader in pancreatic cancer research.

Focal Medical is a clinical stage, platform oncology company. Focal has innovated the drug delivery method through the use of electricity for local and precise delivery of small molecules to pancreatic and other cancers. Their local drug delivery platform amplifies a drug's therapeutic index over systemic administration by delivering 10 to 100 times the drug directly to the target solid tumor, shrinking tumors, while virtually eliminating all systemic exposure and the harsh side effects of chemotherapy which affects the entire body. 

This is an invitation only event. Please RSVP if you would like to join. All guests must be registered with the front desk to gain entrance.

No Offer or Solicitation. This information in this communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus.. This registration does not constitute an offer or solicitation with respect to the purchase or sale of any security in any jurisdiction in which such offer or solicitation is not authorized or to any person to whom it would be unlawful to make such offer or solicitation.